PFE Pfizer Inc
FY2024 10-K
Pfizer Inc (PFE) filed its fiscal year 2024 10-K annual report with the SEC on Feb 27, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core pharmaceutical business focused on innovative medicines and vaccines
- • No new products, services, or business segments introduced or emphasized in this filing
Management Discussion & Analysis
- • Revenue $100.3B, up 8% YoY from $92.9B in prior year
- • Operating margin 27.5% vs 26.1% YoY, driven by cost efficiencies
Risk Factors
- • Regulatory risk from FASB's December 2023 guidance mandating enhanced income tax disclosures, effective 2025, increasing financial statement note complexity
- • Geopolitical risk limited as 10% USD currency fluctuations expected to have no significant net income impact as of Dec 31, 2024
Financial SummaryXBRL
Revenue
$63.6B
Net Income
$8.0B
Net Margin
12.6%
ROE
9.1%
Total Assets
$213.4B
EPS (Diluted)
$1.41
Operating Cash Flow
$12.7B
Source: XBRL data from Pfizer Inc FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Pfizer Inc Annual Reports
Get deeper insights on Pfizer Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.